Biocracked
**Approach: Conceptual metaphor. Palette: D, bold color field.**

A single clear glass of water sits on a saturated mustard-yellow backdrop, shot at a slight low three-quarter angle. A hand-held pen injector rests beside it, its body a matte white with a small electric green dial ring as the only green accent. Hard but clean studio light from the upper left throws a crisp, defined shadow across the yellow surface. Through the glass, the injector is refracted into two slightly offset images, suggesting a signal that is split and hard to read. The mood is calm, questioning and balanced, with no drama. The background is fully warm and bright, with no blue cast. The surface has a subtle paper-like texture. There is no text, no label and no face.
Metabolism

Do Ozempic and Mounjaro Cause Depression? What 20 Studies Found

Dr. Synapse · · 4 min read

The Scary Headline vs. the Data

A few years ago, reports of mood changes and suicidal thoughts in people taking GLP-1 drugs began circulating. Regulators took notice. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) both reviewed the concern. A new systematic review in the Rambam Maimonides Medical Journal now pulls the evidence together, and the headline finding is reassuring: randomized trial evidence shows no increased risk of suicidality, depression, or anxiety with GLP-1 receptor agonists (like semaglutide) or tirzepatide.

The full picture has caveats, though, and they matter.

What the Researchers Did

The authors searched PubMed/MEDLINE, Embase, Web of Science, and Scopus through March 15, 2026, limited to English-language studies in adults aged 18 and over with type 2 diabetes or obesity. They followed PRISMA 2020 reporting standards, plus the PRISMA-S and PRISMA-Harms extensions. In all, 20 studies and two regulatory reviews met the inclusion criteria.

The evidence was sorted into prespecified groups:

  1. Randomized syntheses
  2. Comparative observational studies and target-trial emulations
  3. Outlier studies without an active comparator
  4. Pharmacovigilance (adverse-event reporting) analyses
  5. Regulatory reviews

The authors appraised bias with Cochrane's RoB 2 tool and ROBINS-I, and summarized certainty using GRADE. They emphasized the difference between signal detection (something looks off in the data) and causal inference (the drug actually did it).

The Key Findings, Scannable

Randomized evidence: no increased risk

The strongest evidence came from randomized trials, including two large 2025 meta-analyses and post hoc pooled analyses of semaglutide and tirzepatide. None showed increased suicidality, depression, or anxiety.

Real-world cohorts: no clear increase

Active-comparator cohort studies from the United States, Scandinavia, and the United Kingdom also found no clear increase after controlling for confounding. Active-comparator designs match GLP-1 users against people on other diabetes or weight-loss drugs, which makes the comparison fairer.

Where the alarming signals came from

Passive-comparator studies and disproportionality analyses did generate signals. According to the review, these designs could not separate drug effects from three other explanations:

  • Baseline psychiatric risk
  • Distress related to obesity
  • Reporting bias

These designs are useful for raising questions, but they are weak at answering them. People living with obesity already have higher rates of depression and anxiety, so a raw comparison against people without these conditions can mislead.

The EMA and FDA conclusions, as summarized by the authors, do not support a causal class-wide association between GLP-1 RAs and suicidal ideation or behavior.

The Fine Print: Why This Isn't a Blank Check

The authors conclude that evidence does not support a clinically meaningful increase in neuropsychiatric harm in the populations studied. The wording is deliberate, and several limitations apply:

  • Trials excluded people with psychiatric illness. The review notes that psychiatric exclusion criteria limited generalizability. The people most worried about mood effects are often the ones least represented in the randomized data.
  • Rare, long-term outcomes remain uncertain. Surveillance is still warranted here.
  • Obesity-only populations are flagged for continued monitoring.
  • Patients with substantial psychiatric morbidity are also flagged for surveillance.
  • Observational data can't fully eliminate confounding, even with modern methods.
  • The review is limited to English-language studies in adults with type 2 diabetes or obesity. It does not address children or other conditions.

Practical Takeaways

This is a safety review of prescription drugs, not a study of a supplement. It tested no doses or timing strategies, so it offers no dosing or timing guidance. Your prescriber's instructions and the product label are the right source for that.

What the evidence supports:

  • If you are an adult with type 2 diabetes or obesity, current evidence does not show that semaglutide or tirzepatide (the active ingredients in Ozempic/Wegovy and Mounjaro/Zepbound) raises the risk of depression, anxiety, or suicidality.
  • Mood changes during rapid weight loss can still happen for many reasons. Report them rather than assuming they are harmless or drug-caused.

Who should pay extra attention:

  • People with a history of significant psychiatric illness, since they were underrepresented in trials. The review calls for ongoing surveillance in this group, not avoidance.
  • People using these drugs for obesity alone, a population the authors flag for continued monitoring.

Who should skip it? The review does not identify any group that should avoid these drugs on neuropsychiatric grounds. Whether a GLP-1 drug is right for you depends on your full medical history and is a decision for you and your clinician.

If you notice new or worsening low mood, anxiety, or thoughts of self-harm, contact your healthcare provider promptly. In the US, you can call or text 988 for the Suicide & Crisis Lifeline. Don't stop or change your medication on your own without medical advice.

Bottom Line

The best-controlled evidence points the same way: no increased suicidality, depression, or anxiety, and no regulator-confirmed causal link. The frightening signals trace largely to study designs that can't untangle drug effects from pre-existing risk and reporting bias. The remaining questions concern patients with serious psychiatric histories and very rare, long-term outcomes. For those, the honest answer is that monitoring should continue.

This article summarizes a published review and is not medical advice.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 3, the human outcome, in palette B, warm.

Low three-quarter rear angle, shot with a 50mm lens at shallow depth of field. A middle-aged person's forearm and hand grip a loaded barbell mid-deadlift, the tendons and the muscle of the forearm clearly defined, with chalk dust hanging in the air. Their face is out of frame. The setting is a plain home garage gym with a rubber floor and a rack softly blurred in the background. Low golden-hour sunlight comes through an open roll-up door and rakes across the skin and the knurled steel, casting long warm shadows. Amber, copper and honey tones dominate, with matte black plates for contrast. A tiny electric green silicone wristband or a small green pen injector resting on a nearby shelf adds a subtle accent. The mood is determined, quiet and hopeful.
metabolism

On Tirzepatide? Lifting Weights Saved 1.1 kg of Lean Mass

BY REX MERIDIAN ·

Tirzepatide can melt away over 22 kg in 40 weeks, but it also takes lean tissue and strength with it. A new randomized trial of 120 adults tested whether lifting weights three times a week could change that. Fat loss stayed the same, but lifters lost about 1.1 kg less lean soft tissue. Strength fell in the drug-only group and rose in every test among lifters. Here are the numbers and what they mean for anyone on Mounjaro or Zepbound.

Approach: 3, the human outcome, here as an animal-science moment. Palette: C, natural.

An old female lab mouse with slightly greying, ruffled fur sits upright on a researcher's open gloved palm, photographed at eye level in a close side-on view with a shallow depth of field. Behind it, a softly blurred animal facility window pours in real morning daylight, giving the scene a pale green-grey and warm-wood setting. The nitrile glove is a vivid electric green (#00e676), the single saturated accent. The mouse's whiskers and pink ears catch the light, and the researcher's white coat sleeve is just visible. Tones are natural: skin, soft cream bedding, sage walls. The mood is calm, careful and quietly hopeful, and it conveys age and care rather than drama. The image has no text, no labels and no readable writing.
longevity

Ozempic's Active Ingredient Extended Lifespan in Old Mice. Here's Why

BY DR. SYNAPSE ·

Semaglutide, the active ingredient in Ozempic and Wegovy, extended lifespan in old female mice in a new Nature study from UC Berkeley. Treatment began at 20 months of age and mimicked many benefits of calorie restriction. In a direct comparison, the drug also showed more favourable trajectories than matched calorie restriction in exploratory drive, spatial memory and glucose control. But this is mouse research in females only, with no dosing guidance for humans. Here is what the findings suggest, and what they do not.

Approach: Macro science, the human outcome angle through tissue. Palette: D, bold color field.

Extreme close-up of a cross-section of raw beef thigh muscle, used as a stand-in for human thigh tissue. It is shot straight on and slightly from above, on a saturated tomato-red seamless backdrop. Fine white fat marbling threads run through the dark red muscle fibers. On one half the marbling is dense and lacy, and on the other it is sparse and clean, so the contrast reads as a before and after. A thin, translucent calipers-style steel ruler lies along the edge, with no markings readable. Lighting is soft, directional studio light from the upper left, with crisp highlights on the glistening fibers and gentle warm shadows. A single small electric green surgical marker dot sits on the tissue. The mood is analytical, tense and uncertain, with shallow depth of field and sharp detail on the fat texture.
longevity

High-Dose Semaglutide and Thigh Muscle: What the MRI Shows

BY HELIX WARD ·

A new MRI sub-analysis of the STEP UP trial examined what 72 weeks of high-dose semaglutide (7.2 mg) does to body composition, including the thigh muscles. Fat loss was large, about 11 liters versus placebo, and fat infiltration within thigh muscle fell significantly. Thigh muscle volume dropped by about 1.1 L, a change that missed statistical significance (p = 0.07) but whose confidence interval leans toward loss. With only 55 scanned participants, just six on placebo, and Novo Nordisk involvement, the findings are suggestive rather than conclusive. Here's what the data show, what they can't, and how to protect your muscle on a GLP-1.

**Approach:** Lab in action. **Palette:** Bold color field, mustard yellow.

A close, slightly high three-quarter view of a hand in a magenta-purple nitrile glove holding a clear 12-well cell culture plate. Each well is filled with salmon-pink culture medium. A multichannel pipette hovers over one well, with a single droplet caught just before it falls. The background is a seamless, saturated mustard-yellow surface and wall, with a soft shadow under the plate. Bright, even studio light comes from the upper left, giving crisp highlights on the plastic rims and a soft glow through the liquid. The depth of field is shallow, so the far wells blur gently. A tiny electric-green cap on a tube sits in the corner of the frame. The mood is calm, precise and curious, with a clean, graphic, editorial feel. No text or labels.
peptides

Semaglutide Didn't Shrink Human Muscle Cells. So Why the Muscle Loss?

BY DR. SYNAPSE ·

Does semaglutide really eat your muscle? A new GeroScience study put the drug straight onto primary human muscle cells from older adults with obesity, and the cells didn't waste. No atrophy genes switched on, no secretome alarms, and GIP even thickened myotubes after eight days. Semaglutide did modestly dial down glycolytic ATP production, and GLP-1 receptors were barely detectable. The findings point toward indirect causes of lean mass loss, like calorie deficit and reduced loading, though a dish is not a body.

This page is available in